Background and rationale

- The MPAC at its inaugural meeting* recognised and recommended that the standing TEG on malaria chemotherapy, be maintained as there is now - and will be in the future - a continual need to review new evidence on malaria chemotherapy.

- The TEG on malaria chemotherapy
  - is constituted by and reports to the MPAC
  - will function in close collaboration with the TEG on antimalarial drug resistance and containment, as the use of antimalarial medicines is inextricably linked with the development of resistance and its containment.

Role and functions

The responsibilities of the TEG:
● based on evidence generated through research and experiences from field operations
  ▪ formulate technically sound and feasible policy on the therapeutic and preventive use of antimalarial medicines;
  ▪ propose norms and standards in malaria chemotherapy, and develop guidelines which provide simple and straightforward treatment recommendations that can be applied even in severely resource-constrained settings;
● review new evidence on malaria case management and define their implications for strategy, policy and planning;
● identify gaps in evidence and suggest specific priority areas of research and development in the field of malaria chemotherapy.
Membership and structure of the TEG

- The TEG will comprise 10 core members and up to 5 co-opted members, serving in their personal capacity.
- The membership will include experts on malaria chemotherapy, public health, policy makers and implementers from endemic countries.
- The following areas of expertise should be represented:
  - Epidemiology and public health
  - Clinical management - Paediatrician /adult physician
  - Clinical trials of antimalarial medicines
  - Pharmacology and therapeutics
  - Pharmacokinetics of antimalarial drugs
  - Pathology and pathophysiology of malaria
  - Guidelines development methodology
The TEG members

- will be selected by a nomination panel appointed by MPAC and GMP.
- shall be appointed to serve for an initial term of up to three years, renewable once, for a period of up to an additional three years.
- appointment may be terminated by WHO, including for any of the following reasons:
  - failure to attend two consecutive TEG meetings;
  - change in affiliation resulting in a conflict of interest;
  - a lack of professionalism involving, for example, a breach of confidentiality
- prior to being appointed or renewed, shall be subject to a conflict of interest assessment by WHO, based on the WHO Declaration of Interest procedure,
- shall also be required to sign and abide to the WHO confidentiality agreement
Structure

- The TEG will have 2 co-chairpersons selected from among the appointed members.
- Each chairperson will serve for 3 years, renewable once.
- At least one member of MPAC should serve as a member of the TEG.
- Rapporteurs will be elected at each meeting as required.
- Diagnosis, Treatment and Vaccines unit (DTV), will serve as secretariat.
- GMP with approval of the chairpersons, may invite
  - observers to the TEG meetings, including representatives from non-governmental organization, international professional organizations, technical agencies, and donor organizations.
  - additional experts, and Technical Resource persons, as appropriate, to contribute to specific agenda items.
- Relevant staff from WHO Headquarters (other departments), and Regional Offices will attend as members of the Secretariat.
Working Procedures

- The technical focal point in the DTV unit will work with the chairpersons to develop a plan for routine operations of the TEG.
- The TEG will meet and/or conduct teleconferences as needed to ensure timely review of new evidence.
- When practicable, the TEG meetings will be scheduled in association with the TEG on drug resistance and containment and will have a joint session when indicated.
- Specific topics may be addressed by ad-hoc Evidence Review Groups (ERG), and the TEG will take note of ERG report and recommendation in their reviews of the evidence and further deliberations.
- Decisions on TEG recommendations will, as a rule, be taken by consensus. In the exceptional situation that consensus cannot be reached the chairperson shall report the majority and minority views.
Dissolution of TEG

- The relevance of the TEG will be assessed regularly by the MPAC.
- The terms of reference will also be reviewed once a year by the TEG.
  - Any proposed changes in the ToR must be submitted to and approved by the MPAC.